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1003Economic Outcomes in the Study of Myocardial Perfusion and Coronary Anatomy
Imaging Roles in Coronary Artery Disease RegistryThe SPARC StudyObjectives TSeehe goal of this study was to compare the economic outcomes of patients undergoing different noninvasive tests to
evaluate suspected coronary artery disease (CAD).Background Evaluation of noninvasive tests is shifting to an assessment of their effect on clinical outcomes rather than on their
diagnostic accuracy. Economic outcomes of testing are particularly important in light of rising medical care costs.Methods We used an observational registry of 1,703 patients who underwent coronary computed tomography angiography
(CTA) (n ¼ 590), positron emission tomography (PET) (n ¼ 548), or single-photon emission computed tomography
(SPECT) (n ¼ 565) for diagnosis of suspected CAD at 1 of 41 centers. We followed patients for 2 years, and
documented resource use, medical costs for CAD, and clinical outcomes. We used multivariable analysis and
propensity score matching to control for differences in baseline characteristics.Results Two-year costs were highest after PET ($6,647, 95% conﬁdence interval [CI]: $5,896 to $7,397), intermediate after
CTA ($4,909, 95% CI: $4,378 to $5,440), and lowest after SPECT ($3,965, 95% CI: $3,520 to $4,411). After
multivariable adjustment, CTA costs were 15% higher than SPECT (p < 0.01), and PET costs were 22% higher than
SPECT (p < 0.0001). Two-year mortality was 0.7% after CTA, 1.6% after SPECT, and 5.5% after PET. The incremental
cost-effectiveness ratio for CTA compared with SPECT was $11,700 per life-year added, but was uncertain, with
higher costs and higher mortality in 13% of bootstrap replications. Patients undergoing PET had higher costs and
higher mortality than patients undergoing SPECT in 98% of bootstrap replications.Conclusions Costs were signiﬁcantly lower after using SPECT rather than CTA or PET in the evaluation of suspected coronary
disease. SPECT was economically attractive compared with PET, whereas CTA was associated with higher costs and
no signiﬁcant difference in mortality compared with SPECT. (J Am Coll Cardiol 2014;63:1002–8) ª 2014 by the
American College of Cardiology FoundationEvaluation of patients with symptoms suggestive of coronary
artery disease (CAD) is an everyday clinical problem, but the
diagnosis is often uncertain after a clinical history, physical
examination, and resting electrocardiogram (ECG) have been
performed. Noninvasive testing is typically used to reﬁne the
probability of CAD estimated from the initial clinical evalu-
ation and to select patients for invasive coronary angiography.
There are many options for noninvasive testing, including
myocardial perfusion imaging with single-photon emission
computed tomography (SPECT), positron-emission to-
mography (PET), and coronary computed tomography
angiography (CTA). Results from series of patients evaluated
with single modalities have been published by many in-
vestigators, but there are few head-to-head comparisons of the
outcomes of alternative test strategies. Consequently, the
comparative effectiveness of different noninvasive cardiac
testing strategies has been difﬁcult to assess.page 1009The SPARC (Study of Myocardial Perfusion and Coro-
nary Anatomy Imaging Roles in Coronary Artery Disease)
registry was a multicenter study designed to collect stan-
dardized clinical data on patients undergoing CTA, PET, or
SPECT and to document their subsequent clinical outcomes
(1). The 90-day clinical follow-up of patients in the SPARC
registry showed that medications were often changed as a
result of testing, and that invasive evaluation was usuallyprompted by abnormal test results (2). The purpose of the
present study was to evaluate the economic outcomes of
using CTA, PET, or SPECT to evaluate patients with
suspected CAD.Methods
The design (1) and initial results (2) of the SPARC registry
have been reported previously. Brieﬂy, SPARC was a pro-
spective observational registry that between May 2006 and
April 2008 enrolled patients undergoing clinically-indicated
CTA (using multidetector CT scanners with 64 slices),
PET, or SPECT at 1 of 41 study centers (40 in the United
States, 1 in Canada). Data were collected prospectively on
standardized forms about patient demographics, cardiac risk
factors, prior medical history, symptoms, and medications.
Results of the imaging study were recorded, as were the
subsequent treatments, including use of invasive coronary
angiography and coronary revascularization. Patients were
followed at 90 days, and 6, 12, and 24 months to document
outcomes: death, myocardial infarction (MI), invasive cardiac
procedures (catheterization, coronary artery bypass graft
surgery [CABG], and percutaneous coronary intervention
[PCI]), noninvasive tests, and use of cardiac medications
(aspirin, angiotensin-converting enzyme inhibitors/angio-
tensin receptor blockers, beta-blockers, calcium antagonists,
clopidogrel, nitrates, and statins).
Abbreviations
and Acronyms
CABG = coronary artery
bypass graft surgery
CAD = coronary artery
disease
CI = conﬁdence interval
CTA = coronary computed
tomography angiography
ECG = electrocardiogram/
electrocardiography
MI = myocardial infarction
PCI = percutaneous coronary
intervention
PET = positron emission
tomography
SPECT = single-photon
emission computed
tomography
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1004In order to compare use of
tests for diagnostic evaluation,
we studied only the patients
without a known history of cor-
onary disease. We measured the
cost of medical care for CAD by
multiplying counts of resource
use by standardized cost weights
(Online Table 1). We used the
2008 Medicare fee schedule as
the basis for the cost of tests
(CTA, PET, and SPECT), pro-
cedures (invasive coronary angi-
ography, CABG, and PCI) and
subsequent events (MI, death).
We used average wholesale prices
to assign costs to cardiac medi-
cations. For the purpose of this
analysis, we included all costs
between study entry and 2 yearsof follow-up, which included the cost of the index study test.
We estimated cumulative radiation exposure from all
cardiac tests and procedures performed on individual pa-
tients, based on the number of procedures in each patient
and average radiation exposures per procedure: 13 mSV for
CTA, 11 mSV for SPECT, 4 mSV for PET, 7 mSV for
invasive coronary angiography, and 15 mSV for PCI (3).
Patients in this study underwent testing by physician
choice, not as a result of randomization. In order to adjust
for differences among patient groups, we developed a pro-
pensity score for use of CTA instead of SPECT, and a
second propensity score for use of PET instead of SPECT.
We developed these 2 propensity score models using
multivariable logistic regression, based only on patients
enrolled in centers that performed both tests of interest,
using baseline clinical characteristics recorded on study data
forms: age, sex, race, weight, height, diabetes, history of
smoking, hypertension, family history of CAD, heart failure,
atrial ﬁbrillation, presence of a pacemaker, prior cardiac
studies, and symptom status (angina, noncardiac pain,
asymptomatic). We compared cumulative 2-year medical
costs for CAD management between test groups after log-
arithmic transformation of the costs because of the skew in
the data, using linear regression analysis that adjusted for the
propensity score and other baseline characteristics.
We performed a cost-effectiveness evaluation using the
observed survival times of patients who died and their pro-
jected remaining life expectancy (based on the age-sex-race–
matched U.S. population) to estimate life-years lost. In a
sensitivity analysis, we assigned 2 life-years lost to every pa-
tient who had anMI and survived the remainder of the follow-
up time (4). In order to control for baseline clinical differences
between test groups, we ﬁrst matched on propensity score
(within 0.01) patients undergoing CTA or SPECT, using a
greedymatching algorithm (5).We calculated the incremental
cost-effectiveness ratio as the difference among matchedpatients in 2-year costs divided by the difference in life-years
lost in the 2 groups. We assessed the uncertainty in the cost-
effectiveness estimate using 10,000 bootstrap resamplings of
the CTA patients and SPECT patients, rematching patients
on propensity score, and recalculating the incremental cost-
effectiveness ratio after each resampling. We calculated the
cost effectiveness of PET relative to SPECT in the same
fashion, using patients matched on the PET versus SPECT
propensity scores within 0.01.
Results
There were 1,703 patients without known CAD included in
the SPARC registry, 565 of whom underwent SPECT, 590
of whom had a CTA, and 548 of whom had PET scanning.
Overall, patients who underwent CTA were the youngest,
and patients who underwent PET were the oldest (Table 1).
Patients who underwent PET were more likely to have
diabetes and hypertension, and less likely to have angina.
Over the subsequent 2 years of follow-up, patients who
underwent CTA were more likely to undergo invasive cor-
onary angiography and to receive coronary revascularization
than patients who underwent SPECT, but were similar to
patients who underwent PET; most of the differences in
invasive procedures were evident at 90 days and persisted for
2 years (Table 2). Use of beta-blockers and statins was
highest after PET and lowest after SPECT (Table 2).
During the 2 years of follow-up, 4 patients who underwent
CTA died (0.7%), 9 patients who underwent SPECT died
(1.6%), and 30 patients who underwent PET died (5.5%); in
addition, a nonfatal MI was documented in 2 patients
(0.3%) who underwent CTA, 7 patients (1.2%) who un-
derwent SPECT, and 6 patients (1.1%) who underwent
PET.
The 2-year costs were highest among the patients who
had PET (mean $6,647, 95% conﬁdence interval [CI]:
$5,896 to $7,797), intermediate among the patients who
had CTA (mean $4,909, 95% CI: $4,378 to $5,440), and
lowest among the patients who had SPECT ($3,965, 95%
CI: $3,520 to $4,411). The unadjusted costs among patients
who had PET were signiﬁcantly higher than those of pa-
tients who had SPECT (p < 0.001), and the unadjusted
costs in patients who had CTA were signiﬁcantly higher
than those of patients who had SPECT (p < 0.0001). After
multivariable adjustment for differences in baseline clinical
characteristics, patients undergoing CTA had 15% higher
costs than patients undergoing SPECT (p < 0.01), whereas
patients undergoing PET had 22% higher costs than pa-
tients undergoing SPECT (p < 0.0001).
On the basis of the duration of observed survival and life
expectancy of patients based on the U.S. life tables, patients
in the CTA group lost a mean of 0.08 years of life, patients
in the SPECT group lost 0.23 years, and patients in the
PET group lost 0.76 years. After adjustment for baseline
characteristics, the difference in survival between CTA
and SPECT was not signiﬁcant (p ¼ 0.07), and the
Table 1 Baseline Characteristics
CTA
(n ¼ 590)
SPECT
(n ¼ 565)
PET
(n ¼ 548)
Age, yrs 59  11* 60  11 63  11x
Female 48 51 59y
White race 86x 68 80x
Diabetes 16x 30 41z
Hypertension 56z 66 73*
Hyperlipidemia 63 60 65
Smoker 16 19 12z
Family history of CAD 37y 29 24*
Angina 84* 78 67z
Heart failure 1x 5 3
Dyspnea 23 24 44x
Atrial ﬁbrillation 5 5 8
Abnormal resting ECG 19 35 42
Prior cardiac testing 29x 4 15x
Likelihood of CAD 55y 51 47*
Values are mean  SD or %. *p < 0.05 versus SPECT. yp < 0.01 versus SPECT. zp <0.001 versus
SPECT. xp < 0.0001 versus SPECT.
CAD ¼ coronary artery disease; CTA ¼ coronary computed tomography angiography; ECG ¼
electrocardiogram; PET ¼ positron emission tomography; SPECT ¼ single-photon emission
computed tomography.
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1005difference between PET and SPECT was also not signiﬁ-
cant (p ¼ 0.07).
In order to estimate the cost effectiveness of CTA
compared with SPECT, we matched patients on propensity
score (Table 3). In the matched cohort of 388 pairs, patients
who had CTA had $1,284 higher costs and 0.11 years
longer survival, implying an incremental cost-effectiveness
ratio of $11,700 per life-year added. This estimate was
quite uncertain in the bootstrap analysis, however, with 13%
of replications indicating lower survival and higher costTable 2 Resource Use and Cost
CTA
(n ¼ 590)
Invasive angiography
90 days 13 (77)
2 yrs 16 (92)
PCI
90 days 6 (37)
2 yrs 7 (43)
CABG
0 days 2 (10)
Two yrs 2 (12)
Medications at 1 yr
ACE/ARB 29 (171)
Beta-blocker 31 (181)
Calcium antagonist 11 (66)
Nitrate 6 (37)
Statin 49 (290)
Cost over 2 yrs
Mean  SD $4,909  $6,575
Median (IQR) $2,820 ($1,777–$4,585)
Values are % (n) unless otherwise indicated.
ACE/ARB ¼ angiotensin-converting enzyme inhibitor/angiotension recept
quartile range (25th to 75th percentile); PCI ¼ percutaneous coronary interamong CTA patients compared with SPECT, and another
10% of replications having a cost-effectiveness ratio
>$50,000 per life year added (Fig. 1). In a sensitivity
analysis that included life-years lost from a nonfatal MI,
CTA added 0.12 life-years and had an incremental cost-
effectiveness ratio of $10,700 per life-year added compared
with SPECT; this estimate was also quite uncertain, with
11% of replications showing lower survival and higher costs
after CTA, and another 7% with a cost-effectiveness ratio
>$50,000 per life-year added.
In order to estimate the cost effectiveness of PET
compared with SPECT, we matched on propensity score
372 pairs of patients undergoing either PET or SPECT
(Table 3). In the matched group, the mean 2-year costs were
higher among patients undergoing PET by $2,292, whereas
survival was 0.36 years shorter among PET patients.
Consequently, SPECT was the “dominant strategy,” with
lower costs and better survival. In the bootstrap analysis,
98% of replications yielded higher costs and poor survival
among PET patients (Fig. 2). These results were essentially
unchanged in the sensitivity analysis that incorporated life-
years cost as a result of a nonfatal MI, with 96% of repli-
cations having higher costs and lower survival after PET
compared with SPECT.
The mean total radiation exposure over the study period
was signiﬁcantly higher (p < 0.0001) for patients who under-
went CTA (15.1 mSV) compared with propensity score–
matched patients who underwent SPECT (11.7 mSV), both
for the initial tests (13 mSV vs. 11 mSV) and for follow-up
tests and procedures (2.1 mSV vs. 0.7 mSV, p < 0.0001).
Mean total radiation exposure was signiﬁcantly lower
(p < 0.0001) after PET (6.0 mSV) than after SPECTSPECT
(n ¼ 565)
PET
(n ¼ 548)
4 (24) 11 (63)
7 (38) 15 (82)
1 (8) 5 (25)
2 (11) 6 (31)
0.4 (2) 2 (9)
0.4 (2) 2 (11)
37 (209) 49 (269)
32 (178) 37 (203)
16 (89) 20 (107)
6 (33) 5 (28)
45 (255) 55 (301)
$3,965  $5,404 $6,647  $8,962
$2,810 ($1,692–$4,436) $3,815 ($2,691–$5,585)
or blocker; CABG ¼ coronary artery bypass graft surgery; IQR ¼ inter-
vention; other abbreviations as in Table 1.
Table 3
Baseline Characteristics of the Test Groups Matched
by Propensity Score
CTA–SPECT PET–SPECT
CTA
(n ¼ 388)
SPECT
(n ¼ 388)
PET
(n ¼ 372)
SPECT
(n ¼ 372)
Mean age, yrs 59.4 59.9 62.6 61.6
Male 52 51 42 43
White race 85 75 78 70
Diabetes 18 20 37 34
Hypertension 60 59 67 72
Hyperlipidemia 67 60 65 61
Smoker 17 15 14 17
Family history of CAD 32 37 27 26
Angina 83 82 70 79
Heart failure 2 1 8 3
Dyspnea 22 21 28 41
Atrial ﬁbrillation 6 3 7 6
Abnormal resting
ECG
18 31 36 40
Prior cardiac testing 6 5 6 6
Likelihood of CAD 0.56 0.51 0.47 0.52
Values are %.
Abbreviations as in Tables 1 and 2.
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1006(11.6 mSV) in propensity score–matched patients; exposure
from the initial test was lower for PET (4 mSV) than for
SPECT (11 mSV), but exposure from follow-up tests and
procedures was higher after PET (2.0 mSV) than after
SPECT (0.6 mSV) (p < 0.0001).Figure 1
Bootstrap Analysis of the Incremental Cost-
Effectiveness Ratio of CTA Compared With SPECT
Each point represents the results of a single bootstrap replication. The difference
in 2-year costs between CTA and SPECT is displayed on the vertical axis, and the
difference in life-years lost on the horizontal axis. The solid line indicates the
$50,000 per life-year threshold, and the numbers indicate the proportion of
replication falling within each sector of the cost-effectiveness plane. CTA ¼ cor-
onary computed tomography angiography; LYA ¼ life-years added; SPECT ¼ single-
photon emission computed tomography.Discussion
This analysis of the SPARC registry suggests that the choice
of noninvasive tests to evaluate patients with suspected
CAD affects subsequent medical costs, with the lowest costs
over 2 years follow-up among patients evaluated by SPECT.
The signiﬁcantly higher costs among patients undergoing
CTA or PET were primarily due to higher rates of subse-
quent invasive cardiac procedures, because there was little
difference in initial costs of testing. The higher costs among
patients evaluated with CTA or PET do not appear to be
explained by differences in baseline characteristics, because
costs remained signiﬁcantly higher even after multivariable
adjustment.
Clinical strategies that lead to higher costs may neverthe-
less provide good value for the added expenditures if patient
outcomes are improved sufﬁciently. Cost-effectiveness anal-
ysis provides a framework within which to weigh costs and
outcomes, and thereby assess value. Quantifying improve-
ment in clinical outcomes is unfortunately more difﬁcult than
measuring costs, and in this study, the differences in clinical
outcomes were too small and uncertain to allow any ﬁrm
conclusions about the relative cost effectiveness of CTA,
PET, and SPECT. Larger and more deﬁnitive studies, such
as the ongoing PROMISE (ProspectiveMulticenter Imaging
Study for Evaluation of Chest Pain) trial (NCT01174550),
are needed to assess the value and cost effectiveness of these
strategies.
The higher rate of invasive coronary angiography after
CTA has been documented previously in some studies (6),
but not in others (7–9). The use of invasive proceduresFigure 2
Bootstrap Analysis of the Incremental Cost-
Effectiveness Ratio of PET Compared With SPECT
Format as in Figure 1. PET ¼ positron emission tomography; other abbreviations
as in Figure 1.
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1007varied with the degree of abnormality seen on the CTA (2),
with very few cardiac catheterizations done in patients with
normal or near-normal CTA ﬁndings, but with a higher rate
of catheterization among patients with an abnormal CTA
(2). This observation suggests that the differences in the
composition of the patient population and in the prevalence
of underlying CAD may explain differences between prior
studies in subsequent use of invasive testing after CTA.
Studies that enrolled younger and lower-risk patient pop-
ulations (9) should have more normal CTA studies and,
consequently, fewer invasive tests than studies with patient
populations that are older, have a higher risk, or both.
Patients undergoing PET in this study were older and
had a number of adverse prognostic factors (e.g., diabetes
and hypertension); they had the highest costs in follow-up
and the worst clinical outcomes. The costs among PET
patients remained higher after adjustment for clinical char-
acteristics, although the statistical methods we used could
not adjust for unmeasured factors, such as frailty, that might
have increased overall costs. PET scanning has not been
studied as intensively as other noninvasive testing methods,
and is used uncommonly to evaluate suspected CAD. It is
important to note that none of the patients in this study had
a prior history of CAD, and that PET testing was not
performed to assess myocardial viability. Our ﬁndings sug-
gest that PET should be evaluated carefully in larger studies
with contemporary controls, ideally in a randomized trial, to
assess its impact on clinical and economic outcomes.
The optimal approach to the evaluation of patients with
suspected CAD has been difﬁcult to deﬁne, in part because
there are many alternative test strategies. Direct clinical
comparisons of the outcomes of different strategies are
limited to 2 or 3 alternatives, whereas decision-modeling
studies have been able to assess a larger number of choices.
A decision model by Garber and Solomon (10) compared
exercise treadmill testing, stress echocardiography, planar
thallium imaging, SPECT, and PET imaging with a
strategy of immediate invasive angiography. They found
SPECT to be much more cost effective than PET for
noninvasive diagnosis, and SPECT to be a better option
than immediate invasive coronary angiography. Their study
did not evaluate CTA, which had not yet been developed. A
similar decision model by Kuntz et al. (11) found exercise
echocardiography and SPECT to be reasonable choices for
patients with intermediate probability of CAD, but invasive
coronary angiography to be optimal for patients with high
pre-test probability of CAD; their study did not evaluate
PET or CTA. Hunink et al. (12) used a decision model to
determine parameters that would indicate a new noninvasive
test could be cost effective compared with stress echocardi-
ography or SPECT, and suggested the cost would have to
be <$1,000 with sensitivity and speciﬁcity of 95% or more.
A systematic review and economic evaluation by Mowatt
et al. (13) suggested that SPECT imaging could be cost
effective compared with exercise ECG. The model of
Hernández and Vale (14) also suggested that SPECT wascost effective compared with exercise ECG or invasive
angiography without noninvasive testing, but did not
consider CTA (or PET) as alternatives. Min et al. (15) used
a decision model to assess 5 strategies using CTA or
SPECT, and projected that strategies based on CTA might
be more cost effective than strategies based on SPECT (15).
Empirical comparisons of outcomes after alternative
noninvasive tests have been performed infrequently, and of
necessity, have been limited to fewer choices. Shaw et al.
(16) found that patients who underwent initial SPECT with
selective cardiac catheterization had lower costs than
patients who underwent routine coronary angiography.
Sharples et al. (17) randomized 898 patients to SPECT, stress
echocardiography, magnetic resonance imaging, or direct
invasive coronary angiography, and found SPECT to be as
useful as immediate invasive angiography with similar costs.
Long-term studies of clinical and economic outcomes
such as the SPARC registry of necessity require prolonged
observation, and hence may not reﬂect contemporary
practicedthe so-called “moving target problem” (18). All of
the imaging tests we studied have continued to evolve,
particularly CTA, which was performed in this study using
64-slice scanners between 2006 and 2008, when there was
less experience in interpreting the images than today. In
addition, newer approaches, such as noninvasive fractional
ﬂow reserve (19), can now provide information on the
functional signiﬁcance of lesions seen on CTA, which may
alter the subsequent use of invasive cardiac procedures (20).
Methods for performing PET and SPECT have also
evolved over time. The ongoing evolution of medical
knowledge and clinical practice underscores the value of
maintaining prospective clinical registries that collect data on
practice and outcomes continuously, and allow tracking of
the “moving target.”
Study limitations. This study has a number of additional
limitations, primarily that mode of testing was chosen by
physicians and not assigned randomly. Consequently, any
differences in outcomes could be the result of residual se-
lection bias that was uncorrected by careful statistical
adjustment. The propensity score method we used cannot
adjust for data that were not recorded on study forms, such
as renal function, or that was not assessed uniformly, such as
left ventricular function. Patients were from multiple
different centers, and despite the use of a common protocol
and data standards, differences in clinical practice patterns
among centers might have affected the clinical and economic
outcomes assessed here. The sample size in this study was
not large enough to deﬁne reliably the effects of the alter-
native tests on subsequent rates of survival and MI, and
consequently, the cost-effectiveness analysis has a wide range
of uncertainty. We do not have data on symptoms or quality
of life during follow-up, so our measure of clinical effec-
tiveness could not account for any improvements in these
outcomes as the result of treatments initiated based on test
results. Finally, this study was performed among stable out-
patients, and the results should not be extrapolated to other
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1008settings, such as evaluation of patients presenting to an
emergency department with acute chest pain.
Conclusions
The use of SPECT myocardial perfusion imaging seems to
be associated with lower costs over 2 years of follow-up than
does the use of CTA or PET, primarily because of fewer
subsequent invasive procedures. Further studies are needed
to compare the cost effectiveness of alternative noninvasive
testing approaches for patients with symptoms suggestive of
CAD.
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